Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients

ConclusionAccording to the estimated 50% effective concentration of lopinavir against SARS-CoV-2 virus in Vero E6 cells (16.7 mg/L), our model showed that at steady state, a dose of 400 mg b.i.d. led to 40% of patients below the minimum effective concentration while a dose of 1200 mg b.i.d. will reduce this proportion to 22%.

http://link.springer.com/10.1007/s00228-020-03020-w

Source: European Journal of Clinical Pharmacology - October 13, 2020 Category: Drugs & Pharmacology Source Type: research